Clinical Trials | October 16, 2025
Merck’s DOR/ISL regimen shows minimal impact on weight and lipids in phase 3 HIV studies
These findings follow positive Phase 3 results presented earlier this year
These findings follow positive Phase 3 results presented earlier this year
New results from telisotuzumab adizutecan (Temab-A) and ABBV-706 demonstrate continued progress in AbbVie's antibody-drug conjugate (ADC) portfolio targeting difficult-to-treat cancers
The new plant will manufacture high-quality Type I borosilicate glass tubing
The new cGMP-compliant HPAPI Laboratory is equipped with state-of-the-art isolators designed to meet Occupational Exposure Band 5 (OEB-5) requirements
Updated indication expands treatment options for patients with ulcerative colitis and Crohn’s disease when tumor necrosis factor (TNF) blockers are clinically inadvisable
New test expands access to early Alzheimer’s assessment, streamlining diagnostic pathways and improving referral efficiency
IND clearance enables initiation of Phase 1c clinical trial in HFpEF patients with elevated endotrophin levels
The Cranbury facility represents a strategic advancement of the company's operations in the Unted States
Speakers are: Ch. A. P. Rameswara Rao, National President, BDMAI; Dr. Paidi Yella Reddy, Founder, President & CEO, Sapala Organics; K. V. Rama Gopal, Site Manager & Executive Director, Clariant India; Dr. K. Nagaiah, Chief Scientist, CSIR - Indian Institute of Chemical Technology, Hyderabad; Dr. Satyanarayana Thirunahari, Senior General Manager - Process Safety & Engineering, Laurus Labs; and Yadavendra Shalgaonkar, Assistant General Manager - Tube Sales, Alleima India
Subscribe To Our Newsletter & Stay Updated
